PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques

International Journal of Hematology

Volumn 68, Issue 1, 1998, Pages 1-18

  Francis, G E ^a,b   Fisher, D ^a,b   Delgado, C ^a   Malik, F ^a   Gardiner, A ^a   Neale, D ^a  

^a PolyMASC Pharmaceuticals plc   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Polyethylene glycol

Indexed keywords

CYTOKINE; MACROGOL;

COLONY FORMATION; COUPLING FACTOR; DRUG FORMULATION; GENE TARGETING; GENETIC LINKAGE; IMMUNOGENICITY; LIGAND BINDING; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN STABILITY; REVIEW; TARGET CELL;

EID: 0032126845     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(98)00039-5     Document Type: Review

References (55)

1. Francis GE, Delgado C, Fisher D. PEG-modified proteins. In: Ahern TJ, Manning M. Stability of protein pharmaceuticals: in vivo pathways of degradation and strategies for protein stabilization. In: Borchardt, RT, editor, Pharmaceutical Biotechnology, vol 3. New York: Plenum Press, 1991:235-263.
2. Delgado C, Francis GE, Fisher D. Uses and properties of PEG-linked proteins. In: Critical Reviews in Therapeutic Drug Carrier Systems. Boca Raton, FL: CRC Press, 1992:249-304.
3. Francis G.E., Delgado C., Fisher D., Malik F., Agrawal A.K. Polyethylene glycol modification: applications in tumour targeting and cytokine therapy. J Drug Target. 3:1996;321-340.
4. Teske E., Rutteman G.R., van Heerde P., Misdorp W. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma. Eur J Cancer. 26:1990;891-895.
5. Cebon J., Lieschke G.J., Bury R.W., Morstyn G. The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. Br J Haematol. 80:1992;144-150.
6. Zalipsky S. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjug Chem. 4:1993;296-299.
7. Abuchowski A., van Es T., Palczuk N.C., Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 252:1977;3578-3581.
8. Pyatak P.S., Abuchowski A., Davis F.F. Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. Res Commun Chem Pathol Pharmacol. 29:1980;113-127.
9. Yoshimoto T., Nishimura H., Saito Y.et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res. 77:1986;1264-1270.
10. Abuchowski A., Kazo G.M., Verhoest Jr C.R.et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys. 7:1984;175-186.
11. Leonard M., Neel J., Dellacherie E. Synthesis of monomethoxypolyoxyethylene-bound haemoglobins. Tetrahedron. 40:1984;1585-1590.
12. Katre N.V., Knauf M.J., Laird W.J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA. 84:1987;1487-1491.
13. Wie S.I., Wie C.W., Lee W.Y., Filion L.G., Sehon A.H., Akerblom E. Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerogenic conjugates of common allergens with monomethoxypolyethylene glycols of different molecular weights by the mixed anhydride method. Int Arch Allergy Appl Immunol. 64:1981;84-99.
14. Veronese F.M., Largajolli R., Boccu E., Benassi C.A., Schiavon O. Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase. Appl Biochem Biotechnol. 11:1985;141-152.
15. Beauchamp C.O., Gonias S.L., Menapace D.P., Pizzo S.V. A new procedure for the synthesis of polyethylene glycol-protein adducts: effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal Biochem. 131:1983;25-33.
16. Pizzo S.V. Preparation, in vivo properties and proposed clinical use of polyoxyethylene-modified tissue plasminogen activator and streptokinase. Adv Drug Deliv Rev. 6:1991;153-166.
17. Zalipsky S. Active carbonates of polyethylene oxides for modification of polypeptides. PCT Patent Application no. WO 90/13540, 1990.
18. Yoshimoto T., Ritani A., Ohwada K.et al. Polyethylene glycol derivative-modified cholesterol oxidase soluble and active in benzene. Biochem Biophys Res Commun. 148:1987;876-882.
19. Aldwin L., Nitecki D.E. A water-soluble, monitorable peptide and protein crosslinking agent. Anal Biochem. 164:1987;494-501.
20. Goodson R.J., Katre N.V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology. 8:1990;343-346.
21. Harris JM, Yoshinaga K, Paley MS, Herati MR. New activated PEG derivatives for affinity partitioning. In: Fisher D, Sutherland IA, editors. Separations Using Aqueous Phase Systems. Applications in Cell Biology and Biotechnology. London: Plenum Press, 1989:203-210.
22. Delgado C., Patel J.N., Francis G.E., Fisher D. Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem. 12:1990;119-128.
23. Maeda H, Kai Y, Ono K. PEG derivatives, modified peptides and production thereof. EPA 0 340741, 1989.
24. Iwashita Y, Ajisaka K. Blood substitute containing modified hemoglobin. Ajinomoto Co. Inc. Japan, United States Patent, 4,301,144, 1981.
25. Sears BD. Synthetic phospholipid compounds and their preparation. Lipid Specialities Inc., European Patent Office, 0 072 111, 1983.
26. Harris JM, Dust JM, McGill RA. et al. New polyethylene glycols for biomedical applications. In: Shalaby SW, McCormick CL, Butler GB, editors. Water-Soluble Polymers. Washington, DC: American Chemical Society, 1991.
27. McGoff P., Baziotis A.C., Maskiewicz R. Analysis of polyethylene glycol modified superoxide dismutase by chromatographic, electrophoretic, light scattering, chemical and enzymatic methods. Chem Pharm Bull Tokyo. 36:1988;3079-3091.
28. Yoshinga K., Harris J.M. Effects of coupling chemistry on the activity of poly(ethylene glycol)-modified alkaline phosphatase. J Bioactiv Compat Polym. 4:1989;17-24.
29. Richter A.W., Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol. 70:1983;124-131.
30. Tsuji J., Hirose K., Kasahara E., Naitoh M., Yamamoto I. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Int J Immunopharmacol. 7:1985;725-730.
31. Carter M.C., Meyerhoff M.E. Instability of succinyl ester linkages in O2′-monosuccinyl cyclic AMP-protein conjugates at neutral pH. J Immunol Methods. 81:1985;245-257.
32. Parr M.J., Ansell S.M., Choi L.S., Cullis P.R. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta. 1195:1994;21-30.
33. Zalipsky S., Seltzer R., Menon-Rudolph S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotechnol Appl Biochem. 15:1992;100-114.
34. Ouchi T., Hagihara Y., Takahashi K., Takano Y., Igarashi I. Synthesis and antitumor activity of poly(ethylene glycol)s linked to 5-fluorouracil via a urethane or urea bond. Drug Des Discov. 9:1992;93-105.
35. Royer GP. Modifying Enzymes with Polyethylene Glycol and Product Produced Thereby. Pierce Chemical Co., United States Patent, 4,002,531, 1977.
36. Nilsson K., Mosbach K. Immobilization of enzymes and affinity ligands to various hydroxyl group carrying supports using highly reactive sulfonyl chlorides. Biochem Biophys Res Commun. 102:1981;449-457.
37. Veronese F.M., Sartore L., Schiavon O., Caliceti P. A comparative study of enzymatic, structural, and pharmacokinetic properties of superoxide dismutase isolated from two sources and modified by monomethoxypolyethylene glycol using different methods of coupling. Ann NY Acad Sci. 613:1990;468-474.
38. Delgado C, Francis GE, Fisher D. A process for fractionating PEG protein adducts and adduct of PEG and GM-CSF. PCT Patent Application no. WO 90/04606, 1990.
39. Fisher D. Liposomes. European Patent EP 0 445 131 B1, 1989.
40. Delgado C, Francis GE, Fisher D. Coupling of PEG to proteins by activation with tresyl chloride. Applications in immunoaffinity cell partitioning. In: Fisher D, Sutherland IA, editors. Separations Using Aqueous Phase Systems: Applications in Cell Biology and Biotechnology. New York and London: Plenum Press, 1989:211-213.
41. Jeong S.T., Byun S.M. Decreased agglutinability of methoxy-polyethylene glycol attached red blood cells: significance as a blood substitute. Artif Cells Blood Substit Immobil Biotechnol. 24:1996;503-511.
42. Malik F., Delgado C., Knusli C., Irvine A.E., Fisher D., Francis G.E. Polyethylene glycol (PEG) modified granulocyte-macrophage colony stimulating factor (GM-CSF) with conserved biological activity. Exp Hematol. 20:1992;1028-1035.
43. Delgado C., Malik F., Selisko B., Fisher D., Francis G.E. Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems. J Biochem Biophys Methods. 29:1994;237-250.
44. Knusli C., Delgado C., Malik F.et al. Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br J Haematol. 82(4):1992;654-663.
45. Francis GE, Fisher D, Delgado C, Malik F. Polymer modification. PCT Patent Application no. WO 95/06058, 1995.
46. Saifer M.G., Somack R., Williams L.D. Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35 000 to 120 000 Dalton poly-ethylene glycol. Adv Exp Med Biol. 366:1994;377-387.
47. Monfardini C., Schiavon O., Caliceti P., Morpurgo M., Harris J.M., Veronese F.M. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem. 6:1995;62-69.
48. Knauf M.J., Bell D.P., Hirtzer P., Luo Z.P., Young J.D., Katre N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem. 263:1988;15064-15070.
49. Petros W.P. Pharmacokinetics and administration of colony-stimulating factors. Pharmacotherapy. 12:1992;32S-38S.
50. Delgado C., Francis G.E., Malik F., Fisher D., Parkes V. Polymer-derivatized proteins: analytical and preparative problems. Pharm Sci. 3:1997;59-66.
51. Demiroglou A., el-Schlesselman C., Jennissen H.P. A novel reaction sequence for the coupling of nucleophiles to agarose with 2,2,2-trifluoroethanesulfonyl chloride. Angew Chem Int Ed Engl. 33:1994;120-123.
52. Jennissen H.P. Cyanogen bromide and tresyl chloride chemistry revisited: the special reactivity of agarose as a chromatographic and biomaterial support for immobilizing novel chemical groups. J Mol Recogit. 8:1995;116-124.
53. Ohta T., Tairyo Y., Takitani S. An ion chromatographic method for the estimation of tresyl groups on activated supports. Chromatographia. 35:1993;321-324.
54. Gais H.-J., Ruppert S. Modification and immobilization of proteins with polyethylene glycol tresylates and polysaccharide tresylates: evidence suggesting a revision of the coupling mechanism and the structure of the polymer-polymer linkage. Tetrahedron Lett. 16:1995;3837-3838.
55. King J.F., Gill M.S. Alkyl 2,2,2-trifluoroethanesulfonates (tresylates): elimination-addition vs. bimolecular nucleophilic substitution in reactions with nucleophiles in aqueous media. J Org Chem. 61:1996;7250-7255.